Literature DB >> 19694752

Delayed growth of EL4 lymphoma in SR-A-deficient mice is due to upregulation of nitric oxide and interferon-gamma production by tumor-associated macrophages.

Yoshihiro Komohara1, Kenichi Takemura, Xiao Feng Lei, Naomi Sakashita, Mamoru Harada, Hiroshi Suzuki, Tatsuhiko Kodama, Motohiro Takeya.   

Abstract

Class A scavenger receptors (SR-A, CD204) are highly expressed in tumor-associated macrophages (TAM). To investigate the function of SR-A in TAM, wild-type and SR-A-deficient (SR-A(-/-)) mice were injected with EL4 cells. Although these groups of mice did not differ in the numbers of infiltrating macrophages and lymphocytes and in neovascularization, SR-A(-/-) mice had delayed growth of EL4 tumors. Expression of inducible nitric oxide (NO) synthase and interferon (IFN)-gamma mRNA increased significantly in tumor tissues from SR-A(-/-) mice. Engulfment of necrotic EL4 cells induced upregulation of NO and IFN-gamma production by cultured macrophages, and production of NO and IFN-gamma increased in SR-A(-/-) macrophages in vitro. IFN-beta production by cultured macrophages was also elevated in SR-A(-/-) macrophages in vitro. These results suggested that the antitumor activity of macrophages increased in SR-A(-/-) mice because of upregulation of NO and IFN-gamma production. These data indicate an important role of SR-A in regulating TAM function by inhibiting toll-like receptor (TLR)4-IFN-beta signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694752     DOI: 10.1111/j.1349-7006.2009.01296.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  13 in total

1.  CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma.

Authors:  Jie Qian; Huanfa Yi; Chunqing Guo; Xiaofei Yu; Daming Zuo; Xing Chen; John M Kane; Elizabeth A Repasky; John R Subjeck; Xiang-Yang Wang
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

2.  MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis.

Authors:  A Ghoochani; M A Schwarz; E Yakubov; T Engelhorn; A Doerfler; M Buchfelder; R Bucala; N E Savaskan; I Y Eyüpoglu
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

Review 3.  The role of macrophages in anti-tumor immune responses: pathological significance and potential as therapeutic targets.

Authors:  Hirotake Tsukamoto; Yoshihiro Komohara; Hiroyuki Oshiumi
Journal:  Hum Cell       Date:  2021-04-27       Impact factor: 4.174

Review 4.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

5.  Type I IFN, Ly6C+ cells, and Phagocytes Support Suppression of Peritoneal Carcinomatosis Elicited by a TLR and CLR Agonist Combination.

Authors:  Allison M Dyevoich; Karen M Haas
Journal:  Mol Cancer Ther       Date:  2020-03-18       Impact factor: 6.261

Review 6.  Tumour macrophages as potential targets of bisphosphonates.

Authors:  Thea L Rogers; Ingunn Holen
Journal:  J Transl Med       Date:  2011-10-17       Impact factor: 5.531

7.  High density of CD204-positive macrophages predicts worse clinical prognosis in patients with breast cancer.

Authors:  Yuko Miyasato; Takuya Shiota; Koji Ohnishi; Cheng Pan; Hiromu Yano; Hasita Horlad; Yutaka Yamamoto; Mutsuko Yamamoto-Ibusuki; Hirotaka Iwase; Motohiro Takeya; Yoshihiro Komohara
Journal:  Cancer Sci       Date:  2017-07-03       Impact factor: 6.716

Review 8.  Clinical significance of macrophage heterogeneity in human malignant tumors.

Authors:  Yoshihiro Komohara; Masahisa Jinushi; Motohiro Takeya
Journal:  Cancer Sci       Date:  2013-11-29       Impact factor: 6.716

9.  Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease.

Authors:  Yoichiro Kaku; Haruki Imaoka; Yoshitaka Morimatsu; Yoshihiro Komohara; Koji Ohnishi; Hanako Oda; Shinichi Takenaka; Masanobu Matsuoka; Tomotaka Kawayama; Motohiro Takeya; Tomoaki Hoshino
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 10.  Fucoidan as a marine anticancer agent in preclinical development.

Authors:  Jong-Young Kwak
Journal:  Mar Drugs       Date:  2014-01-28       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.